Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Alkermes Begins Phase I Study On Immuno-Oncology Drug

Published 05/25/2016, 11:30 PM
Updated 07/09/2023, 06:31 AM
ACORQ
-
ALKS
-
ANIP
-
TVTX
-

Alkermes plc (NASDAQ:ALKS) announced the commencement of a multi-center phase I study on its immuno-oncology candidate ALKS 4230 (formerly known as RDB 1450). The study will evaluate the tolerability, safety and immunological-pharmacodynamic effects of ALKS 4230 for the treatment of patients with solid tumors.

Alkermes will conduct the study in two stages – a dose-escalation stage followed by a dose-expansion stage. The company expects interim data from the first stage of the phase I study are expected in 2017.

We note that competition in the immuno-oncology market is stiff given the presence of drugs like Opdivo, Keytruda and Yervoy among others.

Apart from ALKS 4230, Alkermes has a robust pipeline consisting of several candidates. Interesting candidates include ALKS 5461 (phase III – major depressive disorder), ALKS 3831 (phase III-schizophrenia), ALKS 8700 (phase III-multiple sclerosis and ALKS 6428 (phase III – to help physicians transfer patients from opioid agonists to antagonist therapy using Vivitrol).

Alkermes is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) , Retrophin, Inc. (NASDAQ:RTRX) and Acorda Therapeutics, Inc. (NASDAQ:ACOR) . While ANI Pharmaceuticals and Retrophin sport a Zacks Rank #1 (Strong Buy), Acorda Therapeutics carries a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. .Click to get this free report >>


ALKERMES INC (ALKS): Free Stock Analysis Report

ACORDA THERAPT (ACOR): Free Stock Analysis Report

RETROPHIN INC (RTRX): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.